Detailed Explanation
Drug-drug interactions represent a significant consideration in clinical research and medical practice, as concomitant medication use is common and can substantially affect the safety and efficacy of investigational products. These interactions may be pharmacokinetic, affecting how drugs are absorbed, distributed, metabolized, or excreted, or pharmacodynamic, affecting the physiological response to drugs through additive, synergistic, or antagonistic effects at target receptors or systems. Understanding potential interactions is essential for appropriate product labeling and safe clinical use.
Pharmacokinetic interactions frequently involve the cytochrome P450 enzyme system, which metabolizes many drugs in the liver. An investigational product that inhibits a CYP enzyme may increase blood levels of co-administered drugs metabolized by that enzyme, potentially causing toxicity. Conversely, enzyme induction may decrease blood levels of co-administered drugs, potentially reducing efficacy. Other pharmacokinetic interactions involve competition for plasma protein binding, alterations in gastrointestinal absorption, or effects on renal excretion through interactions with drug transporters.